Unraveling tumor metabolsim in histological subtypes of non-small cell lung cancer. Prognostic value and targets for therapy.

T. Meijer

Promotor: J. Bussink, J. Kaanders, L. de Geus-Oei
Copromotor: P. Span
Radboud University , Nijmegen, The Netherlands
October 11, 2019


Lung cancer is a leading cause of cancer related death. Approximately 20% of patients with non-small cell lung cancr (NSCLC) are potentially curable with surgery (stage I –resectable stage IIIA), but about half of those die due to recurrent disease. Irresectable stage III NSCLC can be treated with concurrent or sequential chemoradiation. Immunotherapy is an important new asset in the therapeutic armamentarium of this disease. Despite intensive therapy, prognosis remains poor. Locoregional progression and certainly the occurrence of distant metastases remain a major issue. Therefore, further intensification of treatment may be required in these patients.

A pdf file of this publication is available for personal use. Enter your e-mail address in the box below and press the button. You will receive an e-mail message with a link to the pdf file.